To access this material please log in or register

Register Authorize

Irbesartan clinical efficacy in patients with cardiovascular diseases

Evdokimova A. G., Lozhkina M. V., Kovalenko E. V., Evdokimov V. V.

Keywords: AII receptor antagonists, hyperpiesis, treatment, cardiovascular diseases

DOI: 10.18087/rhj.2012.6.1734

Review of the large-scale clinical studies, which have been completed last years, showed that ARBs meet modern requirements to antihypertensive drugs, are effective and safe for treatment of hypertensive patients with different RF and subclinic lesion of the target organs, CHF, atrial fibrillation (AF). Irbesartan has a reputation of a worthy ARB. Due to long-lasting effect of the drug and its active metabolites after termination of the therapy, withdrawal syndrome does not develop. Besides once-daily dosage, it is also easy to administer irbesartan due to independence from food intake. These benefits allow increase of this ARB treatment compliance.
  1. Андрущишина Т. Б., Морозова Т. Е. Антагонисты рецепторов ангиотензина II при лечении кардиоваскулярных заболеваний. Consilium medicum.2009;11 (5):96–101.
  2. Якушин С. С., Никулина Н. Н. Некоторые размышления по поводу использования современных рекомендаций по диагностике и лечению артериальной гипертензии в реальной клинической практике. Место блокаторов рецепторов ангиотензина II среди антигипертензивных препаратов. Consilium medicum. 2009;11 (10):36–41.
  3. Гиляревский С. Р. Современные возможности блокады ренин-ангиотензиновой системы: остаются ли ингибиторы ангиотензинпревращающего фермента препаратами первого ряда? Consilium medicum. 2010;12 (5):18–23.
  4. Остроумова О. Д., Хорьков С. А., Копченов И. И. Возможности антагонистов рецепторов к ангиотензину II в органопротекции у больных с артериальной гипертонией: значение для клинической практики. Consilium medicum.2009;11 (5):29–37.
  5. Романова Е. Е., Кириченко А. А. Влияние блокады ренин-ангиотензин-альдостероновой системы на течение фибрилляции предсердий. Фарматека. 2009;11:18–21.
  6. Морозова Т. Е., Андрущишина Т. Б. Кардиопротективные свойства блокаторов рецепторов ангиотензина II: фокус на лозартан. Системные гипертензии. 2010;2:43–47.
  7. Мотылевская Т. В., Лучков А. Б. Место ирбесартана в современной кардиологической практике. Medpharmconnect. 2010. Доступно на: http://www. medpharmconnect.com
  8. Чазова И. Е., Ратова Л. Г., Амбатьело Л. Г. Все ли сартаны одинаковы? Системные гипертензии. 2010;2:39–42.
  9. Jonston CI. Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl. 1992 Dec;10 (7):S13–26.
  10. Ивлева А. Я. Клиническое применение ингибиторов ангиотензинпревращающего фермента и антагонистов и антагонистов ангиотензина II. – М.: Миклош, 1998. – 158.
  11. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens. 2000;13 (1 Pt 2):18S-24S.
  12. Johnston CI, Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens. 1997;10 (12 Pt 2):306S-310S.
  13. Medical Economics: Avapro (irbesartan) us product information. In Physicians. Desk Reference. 52edn.1998: 1201–1209.
  14. Marino MR, Langenbacher K, Ford NF, Uderman HD. Pharmaco­kinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol. 1998;38 (3):246–255.
  15. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy effects of irbesartan for hypertension an integrated analysis. Hypertension. 1998;31 (6):1311–1316.
  16. Bramlage P, Durand-Zaleski I, Desai N et al. The valie of irbesartan in the management of hypertension. Expert Opin Pharmacother. 2009;10 (11):1817–1831.
  17. Fogari R, Ambrosoli S, Corradi L et al. 24‑hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators Group. J Hypertens. 1997;15 (12 Pt 1):1511–1518.
  18. Недогода С. В. Возможности сартанов в коррекции когнитивных нарушений при артериальной гипертонии. Системные гипертензии.2012;1 (9):11–14.
  19. Brenner BM, Cooper ME, de Zeeuw D et al. The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst. 2000;1 (4):328–335.
  20. Friedrich MG, Dahlöf B, Sechtem U et al. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension – a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. J Renin Angiotensin Aldosterone Syst. 2003;4 (4):234–243.
  21. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361 (9352):117–124.
  22. Lu GC, Cheng JW, Zhu KM et al. A systematicreview of angiotensin receptorblockers in preventing stroke. Stroke. 2009 Dec;40 (12):3876–3878.
  23. Cohen A, Bregman B, Agabiti Rosei E et al. Comparison of irbesartan us felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (The SILVER trial). J Hum Hypertens. 1998;12 (7):479–483.
  24. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345 (12):870–878.
  25. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345 (12):851–860.
  26. Kintscher U, Bramlage P, Paar WD et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol. 20073;6:12.
  27. Мамырбаева К. М., Мычка В. Б., Масенко В. П. и др. Терапия ирбесартаном больных сахарным диабетом типа 2: метаболические эффекты и влияние на перфузию головного мозга. Consilium medicum. Приложение Системные гипертензии. 2006;2:18–22.
  28. Puig JG, Mateos F, Buño A et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens. 1999;17 (7):1033–1039.
  29. Wurzner G, Gerster J, Chiolero A, Maillard M et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001;19 (10):1855–1860.
  30. Braumhakel M, Schlimmer N, Bohm M. Effect of irbesartan on erectile Function in patients with hypertension and metabolic syndrome. Int J Impot Res. 2008;20 (5):493–500.
  31. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359 (23):2456–2467.
  32. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation. 1998;98 (10):946–952.
  33. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106 (3):331–336.
  34. Voors AA, de Jong RM. Treating diastolic heart failure. Heart. 2008;94 (8):971–972.
Evdokimova A. G., Lozhkina M. V., Kovalenko E. V. et al. Irbesartan clinical efficacy in patients with cardiovascular diseases. Russian Heart Journal. 2012;11(6):364-368.

To access this material please log in or register

Register Authorize
Ru En